FY2028 EPS Forecast for LENZ Therapeutics Lowered by Analyst

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Investment analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for LENZ Therapeutics in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $1.10 per share for the year, down from their previous forecast of $1.20. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.02.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $38.00 target price on shares of LENZ Therapeutics in a research report on Thursday. Piper Sandler initiated coverage on LENZ Therapeutics in a research note on Monday, April 14th. They issued an “overweight” rating and a $51.00 price objective for the company. Citigroup raised their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, March 20th. Finally, TD Cowen began coverage on shares of LENZ Therapeutics in a report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, LENZ Therapeutics has a consensus rating of “Buy” and a consensus target price of $46.60.

LENZ Therapeutics Price Performance

LENZ opened at $26.34 on Friday. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93. The company’s 50-day moving average is $24.56 and its 200 day moving average is $27.29. The firm has a market capitalization of $741.37 million, a P/E ratio of -14.88 and a beta of 0.41.

Institutional Trading of LENZ Therapeutics

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of LENZ Therapeutics during the 4th quarter worth $29,000. KLP Kapitalforvaltning AS purchased a new stake in LENZ Therapeutics during the fourth quarter valued at about $46,000. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after purchasing an additional 1,151 shares during the period. Virtus ETF Advisers LLC purchased a new position in shares of LENZ Therapeutics in the fourth quarter worth about $67,000. Finally, GAMMA Investing LLC increased its stake in shares of LENZ Therapeutics by 5,254.1% in the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company’s stock worth $150,000 after purchasing an additional 5,727 shares in the last quarter. 54.32% of the stock is owned by hedge funds and other institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.